Search Results
Real-world analysis of the impact of del(17p) on ibrutinib efficacy in CLL
Ibrutinib’s Efficacy in CLL Patients with Various Gene Mutations
Real-World Support for Ibrutinib as a Treatment for High-Risk CLL
CLL: Optimal approaches for patients with deletion 17p
CLL: Long-term updates on ibrutinib and idelalisib
Big data on efficacy and toxicity levels for ibrutinib in CLL
Ibrutinib for CLL with Deletion 17p
Lori Leslie, MD, on real-world outcomes in CLL patients receiving ibrutinib or chemoimmunotherapy
Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022
Ibrutinib resistance-mechanisms and options in CLL
Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy
Long-Term Efficacy and Safety With Ibrutinib in CLL
